Innoviva Price to Free Cash Flow Ratio 2010-2023 | INVA
Historical price to free cash flow ratio values for Innoviva (INVA) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Innoviva Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-26 |
15.26 |
|
9.43 |
| 2023-12-31 |
16.04 |
$1.62 |
9.91 |
| 2023-09-30 |
12.99 |
$1.35 |
9.60 |
| 2023-06-30 |
12.73 |
$1.24 |
10.26 |
| 2023-03-31 |
11.25 |
$1.36 |
8.29 |
| 2022-12-31 |
13.25 |
$2.12 |
6.26 |
| 2022-09-30 |
11.61 |
$2.62 |
4.43 |
| 2022-06-30 |
14.76 |
$4.03 |
3.66 |
| 2022-03-31 |
19.35 |
$4.16 |
4.65 |
| 2021-12-31 |
17.25 |
$3.86 |
4.47 |
| 2021-09-30 |
16.71 |
$4.00 |
4.18 |
| 2021-06-30 |
13.41 |
$3.08 |
4.35 |
| 2021-03-31 |
11.95 |
$2.85 |
4.19 |
| 2020-12-31 |
12.39 |
$2.76 |
4.49 |
| 2020-09-30 |
10.45 |
$2.60 |
4.03 |
| 2020-06-30 |
13.98 |
$2.45 |
5.72 |
| 2020-03-31 |
11.76 |
$2.24 |
5.25 |
| 2019-12-31 |
14.16 |
$2.27 |
6.24 |
| 2019-09-30 |
10.54 |
$2.22 |
4.74 |
| 2019-06-30 |
14.56 |
$2.25 |
6.47 |
| 2019-03-31 |
14.03 |
$2.21 |
6.36 |
| 2018-12-31 |
17.45 |
$1.97 |
8.85 |
| 2018-09-30 |
15.24 |
$1.83 |
8.35 |
| 2018-06-30 |
13.80 |
$1.66 |
8.31 |
| 2018-03-31 |
16.67 |
$1.39 |
11.98 |
| 2017-12-31 |
14.19 |
$1.18 |
12.00 |
| 2017-09-30 |
14.12 |
$0.95 |
14.84 |
| 2017-06-30 |
12.80 |
$0.85 |
15.11 |
| 2017-03-31 |
13.83 |
$0.72 |
19.12 |
| 2016-12-31 |
10.70 |
$0.65 |
16.43 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.948B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
